Search Within

Hematologic Malignancies Research

Formats
  1. Journal Article (1545)
  2. Meeting Abstract (1260)
  3. Review (76)
  4. Editorial (35)
  5. Book Section (32)
  6. Research Letter (26)
  7. Conference Paper (15)
  8. Correspondence (8)
  9. Guidelines (4)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3005)
  2. GSK Faculty (2450)
  3. Department of Medicine (2318)
  4. Hematologic Malignancies, Division of (2120)
  5. Sloan Kettering Institute Faculty (2052)
  6. Molecular Pharmacology and Chemistry Program Faculty (1632)

More Groups

People
  1. Michel Sadelain (586)
  2. David Scheinberg (502)
  3. Alexander Lesokhin (381)
  4. Carl Landgren (336)
  5. Renier Brentjens (286)
  6. Gabriela Chiosis (281)

More People

Years
  1. 2025 (64)
  2. 2024 (131)
  3. 2023 (175)
  4. 2022 (126)
  5. 2021 (154)
  6. 2020 (173)

More Years

Publications
  1. Blood (660)
  2. Cancer Research (117)
  3. Journal of Clinical Oncology (112)
  4. Clinical Lymphoma, Myeloma and Leukemia (84)
  5. Biology of Blood and Marrow Transplantation (80)
  6. Molecular Therapy (68)

More Publications

Publishers
  1. American Society of Hematology (700)
  2. Nature Publishing Group (375)
  3. Elsevier Inc. (291)
  4. American Association for Cancer Research (245)
  5. American Society of Clinical Oncology (116)
  6. Cell Press (116)

More Publishers

Results (3005)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • An observational, retrospective analysis of retreatment with carfilzomib in the management of patients with multiple myeloma
    Meeting Abstract

    Peterson, T. J.; Korde, N.; Hassoun, H.; Mailankody, S.; Lesokhin, A. M.; Hultcrantz, M.; Shah, U. A.; Smith, E. L.; Lu, S. X.; Landau, H. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Clinical factors associated with improved survival following allogeneic HSCT after CD19 CAR therapy in adult patients with relapsed B-ALL
    Meeting Abstract

    Park, J. H.; Flynn, J.; Gonen, M.; Bernal, Y.; Diamonte, C.; Halton, E.; Wang, X.; Riviere, I.; Sadelain, M.; Brentjens, R. J.
    Blood (2019)

    Fulltext@MSK | Save
  • EASIX and modified-EASIX are early predictors of severe cytokine release syndrome and neurotoxicity in patients treated with chimeric antigen receptor T cells
    Meeting Abstract

    Pennisi, M.; Sanchez-Escamilla, M.; Flynn, J.; Maloy, M. A.; Silverberg, M. L.; Batlevi, Y.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; Devlin, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Harnessing the epichaperome as a therapeutic approach in multiple myeloma
    Meeting Abstract

    Lopes, E. C.; Wang, T.; Jayabalan, D. S.; Taldone, T.; Monge, J.; Contreras, J.; Winnie, Y.; Trujillo, V.; Palak, P.; Lombardi, N.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A multicenter phase II single arm trial of isatuximab in patients with high risk smoldering multiple myeloma (HRSMM)
    Meeting Abstract

    Manasanch, E. E.; Jagannath, S.; Lee, H. C.; Patel, K. K.; Graham, C.; Kaufman, G. P.; Thomas, S. K.; Iyer, S.; Mailankody, S.; Korde, N.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Efficacy and safety of carfilzomib-lenalidomide-dexamethasone (KRd) in newly diagnosed multiple myeloma: Pooled analysis of 4 single-arm studies
    Meeting Abstract

    Landgren, O.; Attal, M.; Kazandjian, D.; Roussel, M.; Jasielec, J. K.; Dytfeld, D.; Anderson, A.; Kervin, T.; Iskander, K.; Mezzi, K.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase 1 first-in-human study of the anti-CD38 dimeric fusion protein TAK-169 for the treatment of patients (pts) with relapsed or refractory multiple myeloma (RRMM) who are proteasome inhibitor (PI)- and immunomodulatory drug (IMiD)-refractory, including pts relapsed/refractory (R/R) or naïve to daratumumab (dara)
    Meeting Abstract

    Kumar, S. K.; Cornell, R. F.; Landgren, O.; Ailawadhi, S.; Higgins, J. P.; Willert, E. K.; Waltzman, R.; Lin, J.; Zhang, Y.; Lublinsky, A. R.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • PTPN11 mutated acute myeloid leukemia (AML) features an abundant epichaperome network and is sensitive to the epichaperome inhibitor PU-H71
    Meeting Abstract

    Kaner, J. D.; Tavakkoli, M.; Toudic, L.; Stevens, B. M.; Jordan, C. T.; Taldone, T.; Chiosis, G.; Ritchie, E. K.; Desai, P.; Samuel, M. B.; more...
    Blood (2019)

    Fulltext@MSK | Save